Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alaunos Therapeutics, Inc. (TCRT : NSDQ)

• Company Description    Alaunos Therapeutics Inc. is a clinical-stage oncology-focused cell therapy company. It focused on developing T-cell receptor therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform. Alaunos Therapeutics Inc., formerly known as Ziopharm Oncology Inc., is based in HOUSTON. Number of Employees: 1

• Price / Volume Information    Yesterday's Closing Price: $1.63 Daily Weekly Monthly 20 Day Moving Average: 11,730 shares Shares Outstanding: 2.54 (millions) Market Capitalization: $4.14 (millions) Beta: -0.97 52 Week High: $4.59 52 Week Low: $1.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.68% -17.31% 12 Week -28.51% -30.03% Year To Date -49.54% -55.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 501 E LAS OLAS BLVD SUITE 300 - FORT LAUDERDALE,FL 33301 USA ph: 346-355-4099 fax: 617-241-2855 ir@alaunos.com http://www.alaunos.com

• General Corporate Information    Officers Holger Weis - Chief Executive Officer and Director Ferdinand Groenewald - Vice President of Finance Michael A. Jerman - Director Robert W. Postma - Director Jaime Vieser - Director Peer Information Alaunos Therapeutics, Inc. (GSAC) Alaunos Therapeutics, Inc. (CASIF) Alaunos Therapeutics, Inc. (ALCD.) Alaunos Therapeutics, Inc. (OMNN) Alaunos Therapeutics, Inc. (CGPI.) Alaunos Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 98973P309 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/13/26 Share - Related Items Shares Outstanding: 2.54 Most Recent Split Date: 7.00 (0.10:1) Beta: -0.97 Market Capitalization: $4.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.22 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 34.92% vs. Previous Quarter: 30.51% Sales Growth vs. Year Ago Period: -25.00% vs. Previous Quarter: -% ROE 06/30/26 - -232.60 03/31/26 - -165.94 12/31/25 - -172.65 ROA 06/30/26 - -158.99 03/31/26 - -123.50 12/31/25 - -123.32 Current Ratio 06/30/26 - 0.77 03/31/26 - 1.63 12/31/25 - 2.45 Quick Ratio 06/30/26 - 0.77 03/31/26 - 1.63 12/31/25 - 2.45 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - -133,666.67 03/31/26 - -136,966.67 12/31/25 - -83,520.00 Book Value 06/30/26 - 0.26 03/31/26 - 0.54 12/31/25 - 0.93 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©